Corium announces manufacturing business acquisition and investment

USA-based CNS specialist Corium and Gurnet Point Capital have announced the acquisition of their manufacturing business and a $100 million equity investment by Webster Equity Partners. The manufacturing business, named Corium Pharma Solutions, transacted with an investment by Webster for more than $400 million in value.

As a result, Corium announced it has separated into two companies – Corium Pharma Solutions, a contract development and manufacturing organization (CDMO), and Corium, a neuroscience therapeutics commercialization company, to best position each business for future growth. Gurnet Point and Webster will jointly own the CDMO, and each will have representatives on the board for both companies.

In the last two years, Corium has achieved significant growth milestones, including receiving US Food and Drug Administration (FDA) approval of, and commercially launching, its lead drug products Azstarys (serdexmethylphenidate and dexmethylphenidate) and Adlarity (donepezil hydrochloride). In addition, Corium has continued to strengthen its CDMO business, including by validating its proprietary CORPLEX technology for use in drug products through the approval of Adlarity. The investment from Webster validates Corium’s historical success in development and manufacturing, particularly for transdermal products, and more recent mome Saventum in commercialization of neuroscience therapies.